Advertisement
Home 2017 September

Monthly Archives: September 2017

Metabolically healthy obese individuals have increased risk of coronary heart disease

Cardiac Disease Events Up in Metabolically Healthy Obese

0
Increased risks of coronary heart disease, cerebrovascular disease, heart failure
Chronic dosing of apricot kernel extract can result in hypoxia and cyanide toxicity

Chronic Dosing of Apricot Kernel Extract May Lead to Hypoxia

0
Self-prescription of kernel extract reported for five years; cyanide toxicity confirmed in blood analysis
For cases of mild atrial fibrillation-related acute ischemic stroke

Warfarin, Rivaroxaban Similarly Safe, Effective

0
Findings among cases of mild atrial fibrillation-related acute ischemic stroke
Adherence to antibiotic guidelines for acute chest syndrome in children with sickle cell disease varies widely

Antibiotic Rx Adherence Varies Widely in Sickle Cell Care

0
Guideline-adherent therapy tied to fewer 30-day readmissions
Bacterial infections that have sickened 39 people in seven states have been linked to puppies sold through Petland

CDC: Human Campylobacter Linked to Pet Store Puppies

0
Campylobacter can spread through contact with dog feces
Romosozumab treatment followed by alendronate is linked to reduced risk of fractures versus alendronate alone for postmenopausal women with osteoporosis

ASBMR: Romosozumab Reduces Fracture Rate in Osteoporosis

0
Reduced risk of new vertebral fractures, nonvertebral fractures for romosozumab and alendronate
For patients with moderate or severe obstructive sleep apnea

AAO-HNS: Improvement in OSA With Cranial Nerve Stimulation

0
Decrease in apnea-hypopnea index, and improvement in oxygen saturation, sleepiness, quality of life
The median cost of cancer drug development is $648.0 million

Median Cost of Cancer Drug Development $648.0 Million

0
Total revenue from sales of 10 drugs was $67.0 billion, with total R&D spending of $7.2 billion
Complete blood cell count parameters at commonly used or optimal thresholds do not offer high accuracy in identifying invasive bacterial infections in febrile infants (≤60 days of age)

‘Modest at Best’ Discriminatory Ability for CBC Test in Infants

0
Findings among febrile infants (≤60 days) with invasive bacterial infections
For patients with locally advanced

Longer Progression-Free Survival for Durvalumab in NSCLC

0
Longer median progression-free survival from randomization, higher response rate with durvalumab